Although the pathological mechanism underlining such corneal disorders remains unclear, it has been hypothesized that either the accumulation of vandetanib metabolites in the corneal epithelium or a direct inhibition of the ocular EGFR may result in alterations of epithelial cell proliferation and migration [62,125]. This evidence concerns the gene EGFR and corneal disorder.